Mariana Manrique

Mariana Manrique

Auto-generated profile, based on publicly available information

Mariana Manrique

Centro de Virología Animal (CEVAN-CONICET), C1414DEM Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2009 in Mucosal Immunology
Verified
Journal Article
Closed access
MMM Manrique
M Manrique
PKPa Kozlowski
Pa Kozlowski
SWS-W Wang
S-W Wang
RWRl Wilson
Rl Wilson
EME Micewicz
E Micewicz
AAA Aldovini
A Aldovini

1 September 2004 in Virology
Verified
Journal Article
Closed access
MMMariana L. Manrique
Mariana L. Manrique
MRMarı́a L. Rauddi
Marı́a L. Rauddi
SGSilvia A. González
Silvia A. González
JAJosé L. Affranchino
José L. Affranchino

15 March 2011 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MMMariana Manrique
Mariana Manrique
PKPamela A Kozlowski
Pamela A Kozlowski
ACAntonio Cobo-Molinos
Antonio Cobo-Molinos
SWShainn-Wei Wang
Shainn-Wei Wang
RWRobert L. Wilson
Robert L. Wilson
AAAnna Aldovini
Anna Aldovini
The efficacy of two SIV DNA plus recombinant modified vaccinia virus Ankara nasal vaccine regimens, one combined with plasmids expressing IL-2 and IL-15, the other with plasmids expressing GM-CSF, IL-12, and TNF-α, which may better stimulate humoral responses, was evaluated in two female rhesus macaque groups. Vaccination stimulated significant SIV-specific mucosal and systemic cell-mediated immunity in both groups, whereas SIV-specific IgA titers were sporadic and IgG titers negative. All vaccinated animals, except one, became infected after intravaginal SIVmac251 low-dose challenge. Half of the vaccinated, infected animals (7/13) promptly controlled virus replication to undetectable viremia for the duration of the trial (130 wk) and displayed virological and immunological phenotypes similar to those of exposed, uninfected individuals. When all vaccinated animals were considered, a 3-log viremia reduction was observed, compared with controls. The excellent viral replication containment achieved in vaccinated animals translated into significant preservation of circulating α4β7high+/CD4+ T cells and of circulating and mucosal CD4+/CM T cells and in reduced immune activation. A more significant long-term survival was also observed in these animals. Median survival was 72 wk for the control group, whereas >50% of the vaccinated animals were still disease free 130 wk postchallenge, when the trial was closed. There was a statistically significant correlation between levels of CD4+/IFN-γ+ and CD8+/IFN-γ+ T cell percentages on the day of challenge and the control of viremia at week 60 postchallenge or survival. Postchallenge immunological correlates of protection were systemic anti-SIV Gag + Env CD4+/IL-2+, CD4+/IFN-γ+, and CD8+/TNF-α+ T cells and vaginal anti-SIV Gag + Env CD8+ T cell total monofunctional responses.

1 March 2008 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
MMMariana Manrique
Mariana Manrique
EMEwa Micewicz
Ewa Micewicz
PKPamela A. Kozlowski
Pamela A. Kozlowski
SWShainn-Wei Wang
Shainn-Wei Wang
DADeepti Aurora
Deepti Aurora
AAAnna Aldovini
Anna Aldovini
The ability of vaccines to induce immunity both in mucosal and systemic compartments may be required for prevention of HIV infection and AIDS. We compared DNA-MVA vaccination regimens adjuvanted by IL-12 DNA, administered intramuscularly and nasally or only nasally. Most of the vaccinated Rhesus macaques developed mucosal and systemic humoral and cell-mediated SHIV-specific immune responses. Stimulation of mucosal anti-Env IgA responses was limited. After rectal challenge with SHIV 89.6P, all vaccinated and naive animals became infected. However, most of the vaccinated animals showed significant control of viremia and protection from CD4+ T cell loss and AIDS progression compared to the control animals. The levels of CD4+ and CD8+ T cell virus-specific responses measured on the day of challenge correlated with the level of viremia control observed later during the chronic infection. Postchallenge viremia levels inversely correlated with the preservation of SHIV-specific CD4+/IL-2+ and CD8+/TNF-α+ T cells but not with CD4+/IFN-γ+ T cells measured over time after challenge. We also found that during the early chronic infection SHIV vaccination permitted a more significant preservation of both naive and memory CD4+ T cells compared to controls. In addition, we observed a more significant and prolonged preservation of memory CD4+ T cells after SHIV vaccination and challenge than that observed after SIV vaccination and challenge. As the antiviral immunity stimulated by vaccination is present in the memory CD4+ T cell subpopulations, its more limited targeting by SHIV compared to SIV may explain the better control of X4 tropic SHIV than R5 tropic SIVs by vaccination.

1 July 2001 in Virus Research
Verified
Journal Article
Closed access
MMMariana L Manrique
Mariana L Manrique
CCCristina C.P Celma
Cristina C.P Celma
SGSilvia A. González
Silvia A. González
JAJosé L Affranchino
José L Affranchino

1 November 2004 in Virology
Verified
Journal Article
Closed access
MMMariana L. Manrique
Mariana L. Manrique
SGSilvia A. González
Silvia A. González
JAJosé L. Affranchino
José L. Affranchino